- #3,431
bhobba
Mentor
- 10,826
- 3,692
The leading vaccine candidate in the sense of producing the best response in preclinical trials is the University of Queensland's Vaccine which will start human trials here in Brisbane July 13. About 120 healthy volunteers aged between 18 and 55 are needed to test the safety of the candidate vaccine, dubbed S-clamp. It produced a strong immune response in mice. When blood from the mice was tested on the SARS-CoV-2 virus in a test tube the virus was killed. The strength of the antibody response to the vaccine in mice was much higher than that achieved in samples from patients who had recovered from the virus. If this vaccine works it indeed could be the magic bullet, stopping the virus cold. Plans to produce millions of doses here in Aus at the CSIRO have been announced, but that needs to be increased to billions. If as effective as hoped I have no doubt that will happen.
Oxford University’s COVID-19 vaccine is being trialled in 6000 people for its level of effectiveness but it did not prevent monkeys from getting infected with the virus and there is concern declining COVID-19 infection rates in the UK could hamper the tests. The university has entered a partnership with pharmaceutical giant AstraZeneca, and along with other manufacturers in Britain, plans to manufacture up to 2 billion doses by September. It is by far the vaccine that is furthest along in development. But pre-clinical trials were not as good as UQ's vaccine and may not provide good immunity - still even some immunity will help - but may not actually be the magic bullet - simply lowering the r0.
Moderna reported last week that eight of the first 45 patients given its jab developed antibodies to the virus but it has not explained what happened to other people in the trial. Additional trials in vaccinated mice showed the product prevented the virus replicating in the rodent’s lungs, the company said. A further 600 volunteers will be given the vaccine in July. Moderna has signed a manufacturing deal with Swiss multinational, chemical and biotechnology company Lonza which aims to produce up to a billion doses per year. I suspect if it proved effective, like Oxford's vaccine, other manufactures will become involved and that 1 billion doses is conservative.
CanSino Biologics the medical science arm of China’s People’s Liberation Army reported in The Lancet this week that 108 people injected with its vaccine developed antibodies to the virus. However it is using and adenovirus (which causes the common cold) as a platform for the vaccine and because this virus is common in the human population, some of those in the trial had already been naturally infected dampening their immune response. It's plans to produce large quantities is unknown.
Inovio’s vaccine is currently in animal trials at the CSIRO in Melbourne. US company Inovio began human testing of its DNA vaccine for COVID-19 on April 6 and has already reported promising results with vaccine recipients demonstrating strong antibody and T cell immune responses after two or three doses of the vaccine. The vaccine did not appear to have any safety issues. One hundred per cent of people developed antibodies in their blood after three doses. Again it's production plans in unknown.
Novavax began human clinical trial of its vaccine in Australia his week. Melbourne company Nucleus Network is conducting the human clinical trials on behalf of the US biotechnology company. Six Australians received the first doses of the vaccine in the initial safety trial. The company is currently negotiating the second phase of clinical trials involving 2000 people in the US and Australia.
Pfizer bioNTech began human clinical trials of its vaccine in early May. The company said if it proves to be safe and effective it could potentially be ready for distribution in the US by the end of the year. It said it can produce millions of vaccine doses in 2020, increasing to hundreds of millions in 2021.
Clover Biopharmaceuticals Australia’s vaccine is about to be put into human trials by Perth based Linear Clinical Research. The S-Trimer vaccine targets a protein that the SARS-COV-2 virus needs to enter host cells. Production plans are not known.
So my sense is we will have a large number of Oxford University's vaccine by September, but its effectiveness is in question - hopefully it will be effective enough to help reduce the spread. Other vaccines are not as far along the development cycle, and will not be available until the end of this year or next year. But as the Oxford University vaccine shows, once proven, and by doing phase 3 trials in parallel with production, we can quickly produce billions of doses, but as of now only the Oxford Vaccine has plans to make that many, that quickly.
Thanks
Bill
Oxford University’s COVID-19 vaccine is being trialled in 6000 people for its level of effectiveness but it did not prevent monkeys from getting infected with the virus and there is concern declining COVID-19 infection rates in the UK could hamper the tests. The university has entered a partnership with pharmaceutical giant AstraZeneca, and along with other manufacturers in Britain, plans to manufacture up to 2 billion doses by September. It is by far the vaccine that is furthest along in development. But pre-clinical trials were not as good as UQ's vaccine and may not provide good immunity - still even some immunity will help - but may not actually be the magic bullet - simply lowering the r0.
Moderna reported last week that eight of the first 45 patients given its jab developed antibodies to the virus but it has not explained what happened to other people in the trial. Additional trials in vaccinated mice showed the product prevented the virus replicating in the rodent’s lungs, the company said. A further 600 volunteers will be given the vaccine in July. Moderna has signed a manufacturing deal with Swiss multinational, chemical and biotechnology company Lonza which aims to produce up to a billion doses per year. I suspect if it proved effective, like Oxford's vaccine, other manufactures will become involved and that 1 billion doses is conservative.
CanSino Biologics the medical science arm of China’s People’s Liberation Army reported in The Lancet this week that 108 people injected with its vaccine developed antibodies to the virus. However it is using and adenovirus (which causes the common cold) as a platform for the vaccine and because this virus is common in the human population, some of those in the trial had already been naturally infected dampening their immune response. It's plans to produce large quantities is unknown.
Inovio’s vaccine is currently in animal trials at the CSIRO in Melbourne. US company Inovio began human testing of its DNA vaccine for COVID-19 on April 6 and has already reported promising results with vaccine recipients demonstrating strong antibody and T cell immune responses after two or three doses of the vaccine. The vaccine did not appear to have any safety issues. One hundred per cent of people developed antibodies in their blood after three doses. Again it's production plans in unknown.
Novavax began human clinical trial of its vaccine in Australia his week. Melbourne company Nucleus Network is conducting the human clinical trials on behalf of the US biotechnology company. Six Australians received the first doses of the vaccine in the initial safety trial. The company is currently negotiating the second phase of clinical trials involving 2000 people in the US and Australia.
Pfizer bioNTech began human clinical trials of its vaccine in early May. The company said if it proves to be safe and effective it could potentially be ready for distribution in the US by the end of the year. It said it can produce millions of vaccine doses in 2020, increasing to hundreds of millions in 2021.
Clover Biopharmaceuticals Australia’s vaccine is about to be put into human trials by Perth based Linear Clinical Research. The S-Trimer vaccine targets a protein that the SARS-COV-2 virus needs to enter host cells. Production plans are not known.
So my sense is we will have a large number of Oxford University's vaccine by September, but its effectiveness is in question - hopefully it will be effective enough to help reduce the spread. Other vaccines are not as far along the development cycle, and will not be available until the end of this year or next year. But as the Oxford University vaccine shows, once proven, and by doing phase 3 trials in parallel with production, we can quickly produce billions of doses, but as of now only the Oxford Vaccine has plans to make that many, that quickly.
Thanks
Bill
Last edited: